Osteoarthritis biotech Carbylan swings for a $75M IPO

Palo Alto, CA's Carbylan Therapeutics has set terms for an IPO worth $75 million at its midpoint, working to get a treatment for osteoarthritis pain through late-stage development. The company plans to move 5.8 million shares at between $12 and $14 each, setting aside another 870,000 shares for its underwriters and tabbing a maximum deal value of $93.4 million. With the proceeds, Carbylan will pay for the ongoing Phase III studies of Hydros-TA, an injectable treatment for arthritic knee pain. The biotech expects to submit the drug for FDA review next year. Filing

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.